The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Worldwide
Joined February 2017
- Tweets2.7K
- Following482
- Followers7.8K
- Likes891
ctDNA clearance is only part of the story. 🎙️
In Episode 523, Jon Chatzkel joins the Uromigos to explore ctDNA findings from EV-304/KEYNOTE-B15, what they reveal about treatment response and recurrence risk, and why further validation is needed before they can guide treatment decisions.
Swipe for the highlights, then hear the full discussion: bit.ly/3Uo7jGT
#Uromigos #BladderCancer #ESMO26
Uromigos retweeted
I think you would be great at it Monty. Definitely got my vote. @DrChoueiri @OncoAlert @neerajaiims @brian_rini @Uromigos @LosUromigos @uromigosjapan
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Two active drugs. A closer look at what each contributes. 🎙️
In Episode 522, Anders Ullén joins the Uromigos to unpack an exploratory three-arm KEYNOTE-905 analysis in cisplatin-ineligible muscle-invasive bladder cancer, discussing pembrolizumab’s activity, the added contribution of EV, and the balance between efficacy and toxicity.
Swipe for the highlights, then hear the full discussion: bit.ly/4iv9Mro
#Uromigos #BladderCancer #ESMO26
Similar response rates. Different trial outcomes. 🎙️
In Episode 521, Rob Jones joins the Uromigos to unpack differing chemotherapy–immunotherapy trial results in muscle invasive bladder cancer, what pathologic complete response really tells us, and how patient selection may shape outcomes.
Swipe for the highlights, then tune in for the full discussion: bit.ly/4eZI6ts
#Uromigos #ESMO26
A little something to celebrate! 🎙️
The Uromigos podcast has been recognized by @_feedspot as one of the Top 100 Oncology Podcasts!
A BIG thank you to our incredible guests, listeners, and the global oncology community for being part of the conversation.
🎧 Join the conversation wherever you listen to podcasts!
Uromigos retweeted
Amazing APCCC prostate consensus statement out today on early prostate cancer. Experts from around the world come together in Lugano to address the most contravercial issues. @Silke_Gillessen @neerajaiims @DrChoueiri @OncoAlert kwnsfk27.r.eu-west-1.awstrac…
Uromigos retweeted
Such an impt trial and lots to learn from it. Agree completely w your conclusions.
IMmotion 151 clusters are often cited using various and sometimes inaccurate methods. This manuscript describes an individual sample model to be applied moving forward.
Several groups have attempted to predict the IM151 RCC clusters with flawed methods. We developed IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC; available at irisrcc.vindhyadatascience.c…), to predict clusters using an individual-sample model.
nature.com/articles/s41698-0…
ALT Development and validation of IRIS-RCC for predicting molecular subgroups in RCC A. Conceptual figure showing the modeling used to derive the IRIS-RCC predictor B. Cross-validation accuracy metrics for the IRIS-RCC predictor, showing boxplots for overall accuracy and sensitivity, positive predictive value, hazard ratio, and odds ratio for each of the cluster groups. C. Prevalence of the different clusters in the training data (IM151), and validation sets (JR101) using two different methods (Saliby and IRIS-RCC). D. Violin and boxplots showing the enrichment of PD-L1+ IHC levels as a fraction of the total immune cells in Cluster IO compared to Cluster Exclude and Cluster Angio E. Violin and boxplots showing the enrichment of CD8+ IHC levels in Cluster IO compared to Cluster Exclude and Cluster Angio F. Heatmap showing mutational associations with clusters
What do the latest overall survival data from LITESPARK-011 mean for kidney cancer treatment?
Live from #ESMO2026, Dr. Danny Heng joins Brian and Tom to discuss his presentation of LITESPARK-011, including the latest overall survival (OS) data.
🎙️ Episode 529 of The Uromigos Podcast is now live: bit.ly/48hzsCQ
#Uromigos #KidneyCancer #GUOncology
A new Phase 3 study puts triplet therapy in metastatic kidney cancer in the spotlight.
Live from #ESMO2026, Dr. Martin Voss takes over hosting duties to interview Brian and Tom about new Phase 3 data exploring triplet therapy in metastatic clear cell renal cell carcinoma (ccRCC).
🎙️ Episode 528 of The Uromigos Podcast is now live: bit.ly/4zbg4n6
#Uromigos #KidneyCancer #GUOncology
What could new Phase 3 data mean for high-risk prostate cancer?
From #ESMO2026, Dr. Chris Sweeney joins Brian and Tom to discuss new findings from an ANZUP trial, adding to the growing body of Phase 3 evidence in the high-risk prostate cancer setting.
🎙️ Episode 527 of The Uromigos Podcast is now live: bit.ly/4yBisT3
#Uromigos #ProstateCancer #GUOncology
Uromigos retweeted
Excellent presentation by @tompowles1! VOLGA: perioperative durvalumab + 3 cycles of neoadjuvant EV improved EFS (HR 0.51) and OS (HR 0.58) vs cystectomy ± adjuvant therapy in cisplatin-ineligible/declining MIBC. ADCs moving earlier! #ESMO26 @oncoalert @myESMO
Uromigos retweeted
#ESMO26 Phase II sac-TMT + pembro in 1L cisplatin-ineligible advanced UC (n=40, 60% UTUC)
Median PFS 11.2 mo, OS NR and G3/4 TRAEs 63%
Promising results although its place in the EVP era remains to be defined. Worth exploring this combination in other settings
@OncoAlert
Uromigos retweeted
SAC-TMT + pembro shows 68% response rates in metastastic bladder cancer #ESMO2026 . Trofuse-55 explores this combination in bladder sparing approaches in a randomized phase 3. The triplet with EVP seems a justified research randomised question. Triplet data from yesterday showed 81% RRs. @OncoAlert
Uromigos retweeted
Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏
Less is More!
• Cis-inelig MIBC, 25% were cis refusers
• D+EV x3 → RC → adj D x9 (NO adj EV)
• EFS HR 0.51
• OS HR 0.58
• pCR 45 vs 10%
• G3-4 TRAE 30%,
• neuropathy only 18%
• imAEs 33% (G3-4 11%)
• GHS/QoL maintained post-RC
• Treme ↑tox (G3-4 42%, 5 deaths), NO OS gain.
My take: it's not just about chasing bigger numbers. Tox matters too, especially when OS is achieved. Need to discuss the pros and cons with patients.
Less PN and skin tox, and fewer G3+ immune AEs than more cycles and that's a win for patients ! 🙌
@Uromigos @OncoAlert @brian_rini @LosUromigos @drenriquegrande
The #ESMO26 Presidential Symposium is about to begin! 🔥
Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1!
@myESMO
@apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden
Uromigos retweeted
VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert
How are new data reshaping the muscle-invasive bladder cancer landscape?
Live from #ESMO2026, Dr. Michiel van der Heijden joins Brian and Tom following his ESMO discussion and Tom's presentation to unpack the latest findings in MIBC and what they could mean for clinical practice.
🎙️ Episode 526 of The Uromigos Podcast is now live: bit.ly/4kgelIh
#Uromigos #BladderCancer #GUOncology
What can longer follow-up tell us about treatment in metastatic hormone-sensitive prostate cancer?
Live from #ESMO2026, Dr. Karim Fizazi joins Brian and Tom to discuss two presentations featuring long-term follow-up data in mHSPC and what these findings could mean for clinical practice.
🎙️ Episode 525 of The Uromigos Podcast is now live: bit.ly/4icoCmd
#Uromigos #ProstateCancer #GUOncology
Could a new mechanism change how we target prostate cancer?
Live from #ESMO2026, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC, a novel approach that uses the androgen receptor (AR) to target BRD4 and disrupt cancer cell transcription.
🎙️ Episode 524 of The Uromigos Podcast is now live: bit.ly/4z6zWaG
#Uromigos #ProstateCancer #GUOncology
Uromigos retweeted
#ESMO26 KEYNOTE-B15 HRQoL results further support perioperative EVP in MIBC
No clinically meaningful differences in HRQoL despite improved EFS and OS. The greatest deterioration occurred in both arms after surgery (sexual dysfunction)
Congrats @Uro_Oncologist!
@OncoAlert
